Immunotherapy trial aims to spare rectal cancer patients from surgery
NCT ID NCT06640049
Summary
This study is testing whether a drug called dostarlimab can control a specific type of rectal cancer without needing surgery or radiation first. It is for Chinese patients with untreated, locally advanced cancer that has certain genetic markers. The main goal is to see if the drug alone can lead to a lasting disappearance of the cancer for at least 12 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS, RECTAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Chengdu, 610041, China
-
GSK Investigational Site
Chongqing, 400010, China
-
GSK Investigational Site
Guangzhou, 510060, China
-
GSK Investigational Site
Guangzhou, 510655, China
-
GSK Investigational Site
Hangzhou, 310016, China
-
GSK Investigational Site
Hangzhou, China
-
GSK Investigational Site
Jinan, 250117, China
-
GSK Investigational Site
Kunming, 650106, China
-
GSK Investigational Site
Shanghai, 200032, China
Conditions
Explore the condition pages connected to this study.